PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00678626
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 197
- Registration Number
- NCT00678210
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2009-10-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00678106
- Locations
- 🇺🇸
Pfizer Investigational Site, Cleveland, Ohio, United States
Topical CP-690,550 For Chronic Plaque Psoriasis
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT00678561
- Locations
- 🇨🇦
NewLab Clinical Research Inc., St. John's, Newfoundland and Labrador, Canada
🇺🇸Central Dermatology, PC, Saint Louis, Missouri, United States
🇺🇸Dermatology Consulting Services, High Point, North Carolina, United States
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 873
- Registration Number
- NCT00676650
- Locations
- 🇬🇧
Pfizer Investigational Site, Swansea, United Kingdom
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1100
- Registration Number
- NCT00676143
- Locations
- 🇺🇸
UPENN Clinical and Transitional Research Center, Philadelphia, Pennsylvania, United States
🇺🇸Texas Neurology, P.A., Dallas, Texas, United States
🇺🇸Compass Research, LLC, Orlando, Florida, United States
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
- Conditions
- Carcinoma, Adenosquamous CellCarcinoma, Squamous CellCarcinoma, Large CellCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 583
- Registration Number
- NCT00673049
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
- Conditions
- Hepatitis, ChronicHepatitis C Virus
- Interventions
- Drug: Small Molecule Agent (PF-868554)
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00671671
- Locations
- 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States
A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle
- Conditions
- PainSprains and StrainsSprain
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 202
- Registration Number
- NCT00671320
- Locations
- 🇵🇪
Pfizer Investigational Site, Lima, Peru
Varenicline Observational Investigation In The Cessation of Smoking
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 567
- Registration Number
- NCT00669240
- Locations
- 🇸🇮
Pfizer Investigational Site, Maribor, Slovenia